LEGN — Legend Biotech Corp

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1801198 ·
Last close
$16.11
Market Cap
$3.13B
52W High
$37.50
52W Low
$15.75
ADV30
2,451,722
Next earnings
2026-11-10

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 359,500,000 211,900,000 46,800,000 51,700,000 1,681,400,000 460,700,000 408,700,000
Jun 2026 387,500,000 250,100,000 57,700,000 33,200,000 1,750,900,000 672,900,000 521,300,000
Mar 2026 305,100,000 129,200,000 -49,800,000 -54,300,000 1,596,700,000 646,400,000 629,000,000
Dec 2025 306,377,000 182,918,000 -20,602,000 -30,815,000 1,733,700,000 901,900,000 731,600,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-89,400,000
Investing CF
$330,500,000
Financing CF
$166,500,000
CapEx
$-32,400,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.50
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,979,600,000
Inventory
$41,500,000
Receivables
$198,000,000
ST Investments
$291,700,000
EBIT TTM
$-33,855,000
Pretax Income TTM
$-56,272,000
Interest Exp TTM
$22,417,000
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,271,399,936
EBITDA
$-41,600,000
Free Cash Flow
$27,193,000
Enterprise Value
$2,925,462,784
Total Cash
$964,600,000
Total Debt
$278,200,000
Shares Out
194,488,413
Trailing EPS
$-0.50
Book Value
$6.35
ROE
-8.1%
ROA
-1.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,028,900,000 -136,500,000 -296,800,000 1,733,700,000 731,600,000 1,002,100,000 -100,200,000
Dec 2024 627,300,000 -309,500,000 -177,000,000 1,670,200,000 629,600,000 1,040,600,000 -144,000,000
Dec 2023 285,100,000 -528,100,000 -518,300,000 1,848,609,000 597,238,000 1,251,371,000 -393,300,000
Dec 2022 117,005,000 -455,620,000 -446,349,000 1,330,963,000 586,651,000 744,312,000 -201,281,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.05

Max Pain — expiry 2026-12-18

max pain strike: $22.50 · spot: $16.25 · call oi: 3,940 · put oi: 4,147
Expected Move to 2026-12-18: ±$2.97 (18.31%) — implied range $13.28 – $19.23 · ATM straddle on $15.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ACAD ACADIA PHARMACEUTICALS INC $3.17B $18.32 —
BHC Bausch Health Companies Inc. $3.17B $8.47 —
BGM BGM Group Ltd. $3.09B $8.13 —
XERS Xeris Biopharma Holdings, Inc. $3.07B $16.80 —
TLX Telix Pharmaceuticals Ltd $3.01B $8.85 —

News headlines (Yahoo Finance, 1h cache)

Is Return To Profit Altering The Investment Case For Legend Biotech (LEGN)?
2026-11-19 04:29 · Yahoo
Is Legend Biotech (LEGN) Reasonable After CARVYKTI Sales Growth?
2026-11-12 03:14 · Yahoo
Legend Biotech's Carvykti Positioned to Sustain Growth Into 2027, RBC Capital Markets Says
2026-11-11 16:43 · Yahoo
Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript
2026-11-11 03:31 · Yahoo
Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36% as ...
2026-11-10 21:05 · Yahoo
LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy
2026-11-10 20:11 · Yahoo
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
2026-11-10 12:00 · Yahoo
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
2026-11-04 14:00 · Yahoo
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
2026-10-29 12:30 · Yahoo
Legend Biotech (LEGN) Stock Could Trade Below Its Sales Backdrop
2026-10-28 06:20 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.